Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections

Ferguson, Elaine L. ORCID:, Azzopardi, Ernest ORCID:, Roberts, Jessica L., Walsh, Timothy R. ORCID: and Thomas, David W. ORCID: 2014. Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections. Molecular Pharmaceutics 11 (12) , pp. 4437-4447. 10.1021/mp500584u

[thumbnail of 68623.pdf]
PDF - Supplemental Material
Download (1MB) | Preview
[thumbnail of dextrin-colistin antimicrobial EF mol pharm revised.pdf]
PDF - Accepted Post-Print Version
Download (649kB) | Preview
[thumbnail of Ferguson et al figures.pdf]
PDF - Supplemental Material
Download (1MB) | Preview


Polymer therapeutics offer potential benefits in the treatment of multidrug resistant (MDR) infections; affording targeted delivery of biologically active agents to the site of inflammation, potential decreases in systemic toxicity, and the retention of antimicrobial activity at the target site. As a prototype model, these studies developed and characterized a library of dextrin–colistin conjugates (dextrin molecular weight: 7500–48 000 g/mol) as a means of targeting the delivery of colistin. Optimum colistin release kinetics (following dextrin degradation by physiological concentrations of amylase (100 IU/L)) were observed in conjugates containing low molecular weight (∼7500 g/mol) dextrin with ∼1 mol % succinoylation (∼80% drug release within 48 h, compared to ∼33% from sodium colistin methanesulfonate (CMS, Colomycin)). These conjugates exhibited comparable antimicrobial activity to CMS in conventional MIC assays against a range of Gram-negative pathogens, but with significantly reduced in vitro toxicity toward kidney (IC50 = CMS, 15.4 μg/mL; dextrin–colistin, 63.9 μg/mL) and macrophage (IC50 = CMS, 111.3 μg/mL; dextrin–colistin, 303.9 μg/mL) cells. In vivo dose-escalation studies in rats demonstrated improved pharmacokinetics of the conjugates, with prolonged plasma levels of colistin (t1/2 135–1271 min vs 53 min) and decreased toxicity, compared to colistin sulfate. These studies highlight the potential utility of “nanoantibiotic” polymer therapeutics to aid the safe, effective, and targeted delivery of colistin in the management of MDR infections.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Dentistry
Systems Immunity Research Institute (SIURI)
Subjects: R Medicine > RK Dentistry
R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords: nanomedicines; PUMPT; polymer therapeutics; infection; bioresponsive; Gram-negative bacteria
Publisher: American Chemical Society
ISSN: 1543-8384
Date of First Compliant Deposit: 10 June 2019
Date of Acceptance: 31 October 2014
Last Modified: 25 May 2024 21:37

Citation Data

Cited 31 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics